Skip to main content
Home
OUR XCHANGES
BY TOPIC
ADVANCED THERAPIES
AI IN DRUG DISCOVERY
ANTIBODY THERAPEUTICS
IMMUNOTHERAPIES
MEDTECH STRATEGY
OLIGONUCLEOTIDES & PEPTIDES
BY LOCATION
BOSTON, USA
SAN FRANCISCO, USA
MUNICH, EU
PAST EVENTS
INDUSTRY EXPERTS
ADVANCED THERAPIES
AI IN DRUG DISCOVERY
ANTIBODY DRUG CONJUGATES THERAPEUTICS
ANTIBODY THERAPEUTICS
IMMUNOTHERAPIES
MEDTECH STRATEGY
OLIGONUCLEOTIDES & PEPTIDES
NEWS XCHANGE
PARTNERSHIPS
OUR PARTNERS
BECOME A PARTNER
MEDIA PARTNERS
ABOUT US
GET TO KNOW US
FAQS
MEET THE TEAM
GALLERY
CONTACT US
Home
OUR XCHANGES
BY TOPIC
ADVANCED THERAPIES
AI IN DRUG DISCOVERY
ANTIBODY THERAPEUTICS
IMMUNOTHERAPIES
MEDTECH STRATEGY
OLIGONUCLEOTIDES & PEPTIDES
BY LOCATION
BOSTON, USA
SAN FRANCISCO, USA
MUNICH, EU
PAST EVENTS
INDUSTRY EXPERTS
ADVANCED THERAPIES
AI IN DRUG DISCOVERY
ANTIBODY DRUG CONJUGATES THERAPEUTICS
ANTIBODY THERAPEUTICS
IMMUNOTHERAPIES
MEDTECH STRATEGY
OLIGONUCLEOTIDES & PEPTIDES
NEWS XCHANGE
PARTNERSHIPS
OUR PARTNERS
BECOME A PARTNER
MEDIA PARTNERS
ABOUT US
GET TO KNOW US
FAQS
MEET THE TEAM
GALLERY
CONTACT US
Sponsorship Enquiry
Register For Free
Home
OUR XCHANGES
BY TOPIC
ADVANCED THERAPIES
AI IN DRUG DISCOVERY
ANTIBODY THERAPEUTICS
IMMUNOTHERAPIES
MEDTECH STRATEGY
OLIGONUCLEOTIDES & PEPTIDES
BY LOCATION
BOSTON, USA
SAN FRANCISCO, USA
MUNICH, EU
PAST EVENTS
INDUSTRY EXPERTS
ADVANCED THERAPIES
AI IN DRUG DISCOVERY
ANTIBODY DRUG CONJUGATES THERAPEUTICS
ANTIBODY THERAPEUTICS
IMMUNOTHERAPIES
MEDTECH STRATEGY
OLIGONUCLEOTIDES & PEPTIDES
NEWS XCHANGE
PARTNERSHIPS
OUR PARTNERS
BECOME A PARTNER
MEDIA PARTNERS
ABOUT US
GET TO KNOW US
FAQS
MEET THE TEAM
GALLERY
CONTACT US
Oligonucleotides & Peptides Xchange - San Francisco - 2025
Loading
Explore how the GLP-1 class (e.g., semaglutide) evolved from a diabetes drug to a global metabolic health blockbuster.
26 Sep 2025
09:05 - 10:05
Translational & Clinical Strategy
Add to Calendar
LinkedIn
YouTube
Search
Search
Search
Username *
Password *
Login
